Bile acids as metabolic regulators

Current Opinion in Gastroenterology

Volumn 31, Issue 2, 2015, Pages 159-165

  Li, Tiangang ^a   Chiang, John Y L ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b Northeastern Ohio Medical University   (United States)

Author keywords

bile acids; diabetes; FGF15 FGF19; incretin; microbiota

Indexed keywords

BILE ACID; BILE ACID SEQUESTRANT; CHOLESTEROL 7ALPHA MONOOXYGENASE; COLESEVELAM; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; LIGAND; PROTEIN TYROSINE PHOSPHATASE SHP 2; UNCLASSIFIED DRUG; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR;

ARTICLE; BARIATRIC SURGERY; BILE ACID METABOLISM; BILE ACID SYNTHESIS; COLON; ENERGY METABOLISM; ENTEROHEPATIC CIRCULATION; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; ILEUM; INTESTINE; INTESTINE FLORA; LIPID METABOLISM; LIVER; MICROFLORA; NEGATIVE FEEDBACK; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POSITIVE FEEDBACK; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN; HOMEOSTASIS; INFLAMMATION; METABOLISM; PATHOLOGY; SMALL INTESTINE; TRANSPORT AT THE CELLULAR LEVEL;

BILE ACIDS AND SALTS; BIOLOGICAL TRANSPORT; CHOLESTEROL 7-ALPHA-HYDROXYLASE; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; INFLAMMATION; INTESTINE, SMALL; LIVER; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION;

EID: 84922758254     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000156     Document Type: Article

References (66)

1. Chiang JY. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev 2002; 23:443-463.
2. Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev 2014; 66:948-983.
3. Lu TT, Makishima M, Repa JJ, et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000; 6:507-515.
4. Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000; 6:517-526.
5. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2:217-225.
6. Yu C, Wang F, Kan M, et al. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 2000; 275:15482-15489.
7. Yu C, Wang F, Jin C, et al. Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids. J Biol Chem 2005; 280:17707-17714.
8. Kong B, Wang L, Chiang JY, et al. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 2012; 56:1034-1043.
9. Song KH, Li T, Owsley E, et al. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alphahydroxylase gene expression. Hepatology 2009; 49:297-305.
10. Lan T, Rao A, Haywood J, et al. Mouse organic solute transporter alpha deficiency alters FGF15 expression and bile acid metabolism. J Hepatol 2012; 57:359-365.
11. Lan T, Haywood J, Dawson PA. Inhibition of ileal apical but not basolateral bile acid transport reduces atherosclerosis in apoE(-)/(-) mice. Atherosclerosis 2013; 229:374-380.
12. Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and nonalcoholic fatty liver disease: new insights. Clin Microbiol Infect 2013; 19:338-348.
13. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444:1027-1031.
14. Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312:1355-1359.
15. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev 2001; 81:1031-1064.
16. Reimer RA, McBurney MI. Dietary fiber modulates intestinal proglucagon messenger ribonucleic acid and postprandial secretion of glucagon-like peptide-1 and insulin in rats. Endocrinology 1996; 137:3948-3956.
17. Kok NN, Morgan LM, Williams CM, et al. Insulin, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide and insulin-like growth factor I as putative mediators of the hypolipidemic effect of oligofructose in rats. J Nutr 1998; 128:1099-1103.
18. Cani PD, Dewever C, Delzenne NM. Inulin-type fructans modulate gastrointestinal peptides involved in appetite regulation (glucagon-like peptide-1 and ghrelin) in rats. Br J Nutr 2004; 92:521-526.
19. Delzenne NM, Cani PD, Daubioul C, Neyrinck AM. Impact of inulin and oligofructose on gastrointestinal peptides. Br J Nutr 2005; 93 (Suppl. 1): S157-S161.
20. Noverr MC, Huffnagle GB. Does the microbiota regulate immune responses outside the gut? Trends Microbiol 2004; 12:562-568.
21. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56:1761-1772.
22. Islam KB, Fukiya S, Hagio M, et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 2011; 141:1773-1781.
23. Clarke SF, Murphy EF, Nilaweera K, et al. The gut microbiota and its relationship to diet and obesity: new insights. Gut Microbes 2012; 3:186-202.
24. Zhang H, DiBaise JK, Zuccolo A, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci USA 2009; 106:2365-2370.
25. Li JV, Ashrafian H, Bueter M, et al. Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut 2011; 60:1214-1223.
26. Furet JP, Kong LC, Tap J, et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 2010; 59:3049-3057.
27. Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 2014; 509:183-188. This study used FXR-deficient mouse models to investigate the role of FXR signaling in mediating the beneficial effects of bypass surgery in promoting weight loss and improving glucose homeostasis.
28. Inagaki T, Moschetta A, Lee YK, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA 2006; 103:3920-3925.
29. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006; 47:241-259.
30. Wostmann BS. Intestinal bile acids and cholesterol absorption in the germfree rat. J Nutr 1973; 103:982-990.
31. Swann JR, Want EJ, Geier FM, et al. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci US A 2011; 108 (Suppl. 1):4523-4530.
32. Sayin SI, Wahlstrom A, Felin J, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013; 17:225-235. This study revealed a novel mechanism by which gut bacteria modulate the enterohepatic signaling regulation of hepatic bile acid synthesis.
33. Hu X, Bonde Y, Eggertsen G, Rudling M. Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism. J Intern Med 2014; 275:27-38. This study demonstrates the importance of bile acid composition in the regulation of hepatic bile acid synthesis in antibiotic-treated mice and in CYP8B1-deficient mice.
34. Mitchell JB, Xavier S, DeLuca AM, et al. A low molecular weight antioxidant decreases weight and lowers tumor incidence. Free Radic Biol Med 2003; 34:93-102.
35. Li F, Jiang C, Krausz KW, et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun 2013; 4:2384. This study reports that alteration of gut microbiome impacts bile acid composition, FXR signaling and metabolic homeostasis.
36. Lin BC, Wang M, Blackmore C, Desnoyers LR. Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 2007; 282:27277-27284.
37. Ito S, Fujimori T, Furuya A, et al. Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. J Clin Invest 2005; 115:2202-2208.
38. Li S, Hsu DD, Li B, et al. Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis. Cell Metab 2014; 20:320-332. This study identified a key signaling component in mediating the FGF15-FGF19 regulation of bile acid synthesis in the hepatocytes.
39. Li S, Hsu DD, Wang H, Feng GS. Dual faces of SH2-containing proteintyrosine phosphatase Shp2/PTPN11 in tumorigenesis. Front Med 2012; 6:275-279.
40. Chan RJ, Feng GS. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 2007; 109:862-867.
41. Wang C, Yang C, Chang JY, et al. Hepatocyte FRS2alpha is essential for the endocrine fibroblast growth factor to limit the amplitude of bile acid production induced by prandial activity. Curr Mol Med 2014; 14:703-711. This study identified FRS as a novel signaling component in mediating the FGF15/ FGF19 regulation of bile acid synthesis in the hepatocytes.
42. Bard-Chapeau EA, Li S, Ding J, et al. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 2011; 19:629-639.
43. Kong B, Huang J, Zhu Y, et al. Fibroblast growth factor 15 deficiency impairs liver regeneration in mice. Am J Physiol Gastrointest Liver Physiol 2014; 306:G893-G902.
44. Uriarte I, Fernandez-Barrena MG, Monte MJ, et al. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of postresection liver failure in mice. Gut 2013; 62:899-910.
45. Luo J, Ko B, Elliott M, et al. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci Transl Med 2014; 6:247ra100.
46. Mouzeyan A, Choi J, Allayee H, et al. A locus conferring resistance to diet induced hypercholesterolemia and atherosclerosis on mouse chromosome 2. J Lipid Res 2000; 41:573-582.
47. Phan J, Pesaran T, Davis RC, Reue K. The Diet1 locus confers protection against hypercholesterolemia through enhanced bile acid metabolism. J Biol Chem 2002; 277:469-477.
48. Vergnes L, Lee JM, Chin RG, et al. Diet1 functions in the FGF15/19 enterohepatic signaling axis to modulate bile acid and lipid levels. Cell Metab 2013; 17:916-928. This study revealed that Diet1 is a novel regulator of enterohepatic FGF15- FGF19 signaling in the regulation of bile acid homeostasis, and provided a molecular link between Diet1 gene and atherogenesis.
49. McCarter SD, Johnson DL, Kitt KN, et al. Regulation of tight junction assembly and epithelial polarity by a resident protein of apical endosomes. Traffic 2010; 11:856-866.
50. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelamin patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008; 168:1531-1540.
51. Staels B, Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 2007; 67:1383-1392.
52. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in noninsulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994; 121:416-422.
53. Brufau G, Stellaard F, Prado K, et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 2010; 52:1455-1464.
54. Sonne DP, Hansen M, Knop FK. Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion. Eur J Endocrinol 2014; 171:R47-R65.
55. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87:1409-1439.
56. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273:E981-E988.
57. Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 1998; 47:530-537.
58. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 2005; 329:386-390.
59. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10:167-177.
60. Harach T, Pols TW, Nomura M, et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep 2012; 2:430.
61. Potthoff MJ, Potts A, He T, et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gastrointest Liver Physiol 2013; 304:G371-G380.
62. Hofmann AF. Bile acid sequestrants improve glycemic control in type 2 diabetes: a proposed mechanism implicating glucagon-like peptide 1 release. Hepatology 2011; 53:1784.
63. Le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006; 243:108-114.
64. Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004; 240:236-242.
65. Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulinindependent activator of hepatic protein and glycogen synthesis. Science 2011; 331:1621-1624.
66. Miras AD, le Roux CW. Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery? Int J Obes 2014; 38:325-333.